- Home
- DOUG vs ALGS Comparison
DOUG vs ALGS Comparison
Compare DOUG & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOUG
- ALGS
- Stock Information
- Founded
- DOUG 1911
- ALGS 2018
- Country
- DOUG United States
- ALGS United States
- Employees
- DOUG N/A
- ALGS N/A
- Industry
- DOUG Building operators
- ALGS Biotechnology: Pharmaceutical Preparations
- Sector
- DOUG Real Estate
- ALGS Health Care
- Exchange
- DOUG Nasdaq
- ALGS Nasdaq
- Market Cap
- DOUG 142.2M
- ALGS 118.8M
- IPO Year
- DOUG N/A
- ALGS 2020
- Fundamental
- Price
- DOUG $1.95
- ALGS $18.63
- Analyst Decision
- DOUG
- ALGS Strong Buy
- Analyst Count
- DOUG 0
- ALGS 1
- Target Price
- DOUG N/A
- ALGS $75.00
- AVG Volume (30 Days)
- DOUG 657.1K
- ALGS 263.3K
- Earning Date
- DOUG 02-27-2025
- ALGS 03-11-2025
- Dividend Yield
- DOUG N/A
- ALGS N/A
- EPS Growth
- DOUG N/A
- ALGS N/A
- EPS
- DOUG N/A
- ALGS N/A
- Revenue
- DOUG $966,442,000.00
- ALGS $5,997,000.00
- Revenue This Year
- DOUG $5.28
- ALGS N/A
- Revenue Next Year
- DOUG $16.40
- ALGS N/A
- P/E Ratio
- DOUG N/A
- ALGS N/A
- Revenue Growth
- DOUG 1.86
- ALGS N/A
- 52 Week Low
- DOUG $1.00
- ALGS $6.76
- 52 Week High
- DOUG $2.98
- ALGS $46.80
- Technical
- Relative Strength Index (RSI)
- DOUG 51.38
- ALGS 33.33
- Support Level
- DOUG $2.00
- ALGS $20.12
- Resistance Level
- DOUG $2.19
- ALGS $24.33
- Average True Range (ATR)
- DOUG 0.14
- ALGS 2.67
- MACD
- DOUG 0.01
- ALGS -0.38
- Stochastic Oscillator
- DOUG 42.86
- ALGS 4.38
About DOUG Douglas Elliman Inc.
Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate. Business is engaged in two operating segments Real Estate Brokerage and Corporate and other. The firm generates income from Commission and other brokerage revenue from existing home sales, Commission and other brokerage income from development marketing, Property management revenue and Title fees.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.